AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00770003
Drug: AZD8848
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
Trial: NCT00770003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal spray solution. Once weekly intranasal administrations for one month.
Trial: NCT01393990
Drug: LY2228820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02919475
Drug: JTE-051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug tablets containing JTE-051
Trial: NCT02919475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical in appearance to the active drug tablets
Trial: NCT02123056
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
Trial: NCT01594723
Drug: 120 mg LY2784544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02688140
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02688140
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02688140
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02720952
Drug: Infacort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dry granule formulation of hydrocortisone
Trial: NCT01080027
Drug: Rebif® New Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
Trial: NCT00830674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose IV or SC administration
Trial: NCT01011322
Drug: LT-02
RxNorm normalized name: LT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
Trial: NCT01011322
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00916890
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
Trial: NCT01200862
Drug: Investigational new drug company code: BGS649
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01200862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01461083
Drug: [18F]MPPF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
Trial: NCT00720798
Drug: Disease-modifying anti-rheumatic drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
Trial: NCT00720798
Drug: Non-steroidal anti-inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
Trial: NCT00720798
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
Trial: NCT02448810
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Investigator's choice~* Dose according to drug label
Trial: NCT00096083
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01438723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prior to CABG surgery 3 day treatment with placebo capsules three times a day
Trial: NCT00975637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC
Trial: NCT01519609
Drug: bowel prep before endoscopy
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bowel prep before colonoscopy
Trial: NCT00198497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00835822
Drug: Venocur Triplex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Trial: NCT00835822
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Trial: NCT00532155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
Trial: NCT01084005
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive placebo matching linagliptin 5 mg once daily
Trial: NCT00600288
Drug: Non-preserved saline solution (Placebo)
RxNorm normalized name: CONTACT LENS SALINE,PRESERVED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 drops administered in each eye 4 times a day for 6 weeks
Trial: NCT02322021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
Trial: NCT03552458
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
Trial: NCT00401882
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine (1 mg) IV additional doses
Trial: NCT03974594
Drug: Trifluridine and Tipiracil Tablets
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
Trial: NCT04558684
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
Trial: NCT04558684
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
Trial: NCT01021579
Drug: Metfomin plus Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03276988
Drug: Period 1 GX-30, Period 2 THYROGEN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
Trial: NCT03276988
Drug: Period 1 THYROGEN®, Period 2 GX-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
Trial: NCT02244437
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02244437
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02367053
Drug: ZP4207
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02011594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT00368537
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
Trial: NCT00685919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 6 hours for 5 doses, given orally, and matching Carbidopa
Trial: NCT03452228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by Intravenous (IV)
Trial: NCT00006170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matched placebo pill
Trial: NCT01783106
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimental
Trial: NCT00322101
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00322101
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01590433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
Trial: NCT03818737
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
Trial: NCT01090973
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses.
Trial: NCT02284360
Drug: APOSEC™ for cutaneous use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure.
Trial: NCT01990885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00497471
Drug: iron (2 mg/kg/daily)
RxNorm normalized name: Iron(2+) fumarate
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01602380
Drug: faslodex dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
Trial: NCT01602380
Drug: arimidex dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet 1 daily
Trial: NCT01717456
Drug: Laxatives or anti-diarrheals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed.
Trial: NCT03753269
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
Trial: NCT03802227
Drug: NKTR-181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of NKTR-181 and oxycodone IR placebo
Trial: NCT00891683
Drug: AEG33773 oral dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
Trial: NCT03770871
Drug: Indirect pulp treatment using Vitrebond (TM )
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial caries removal and protection of the dental pulp with biocompatible material
Trial: NCT02370706
Drug: PIM447
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pan-pim inhibitor
Trial: NCT02370706
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitor
Trial: NCT00239902
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02269748
Drug: Analgesic Therapy
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg TID
Trial: NCT03608371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule matching BTRX-246040 40 mg capsule
Trial: NCT04514029
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg started 2 weeks (+/-5 days) prior to apheresis through day +30
Trial: NCT00479310
Drug: Summers 5% L.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00503516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 sachet of 160 mg of placebo b.i.d.
Trial: NCT00954304
Drug: HM30181AK 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181AK 1mg tablet
Trial: NCT00954304
Drug: HM30181AK 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181AK 5mg tablet
Trial: NCT00954304
Drug: HM30181AK 15mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181AK 15mg tablet
Trial: NCT00954304
Drug: HM30181AK 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181AK 60mg tablet
Trial: NCT03819153
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Trial: NCT03094403
Drug: Finacea® (azelaic acid) Gel, 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel
Trial: NCT03094403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel
Trial: NCT00090168
Drug: MK0653A , ezetimibe (+) simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00090168
Drug: Duration of Treatment: 6 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02275988
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01632046
Drug: lactate and bicarbonate buffered dialysis solutions
RxNorm normalized name: lactate Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
Trial: NCT00634400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02555709
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 matching VTP-43742 administered as an oral capsule once daily
Trial: NCT00691002
Drug: Calcipotriol plus hydrocortisone (LEO 80190)
RxNorm normalized name: hydrocortisone Rectal Cream [Recort Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application
Trial: NCT00691002
Drug: LEO 80190 Vehicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00691002
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02555709
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 matching VTP-43742 administered as an oral capsule once daily
Trial: NCT02616562
Drug: Norditropin® FlexPro® pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once daily.
Trial: NCT02545413
Drug: Probiotic VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05074589
Drug: Irinotecan liposome、5-Fluorouracil、Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan liposome、5-Fluorouracil、Leucovorin
Trial: NCT05074589
Drug: Placebo、5-Fluorouracil、Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo、5-Fluorouracil、Leucovorin
Trial: NCT00962299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a day by metered dose inhaler with spacer for 6 months
Trial: NCT00854009
Drug: BLI-489
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00854009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00664469
Drug: Comparator: Simvastatin 20, 40 and 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Trial: NCT00664469
Drug: Comparator: Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Trial: NCT02595333
Drug: Group SF1
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
Trial: NCT02595333
Drug: Group S1
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil was administered for analgesia in primary cesarean section
Trial: NCT02595333
Drug: Group SF2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
Trial: NCT00610623
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/day, IV from day 1 to 20
Trial: NCT00610623
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once per day, IV from day 1 to 20
Trial: NCT02595333
Drug: Group S2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil was administered for analgesia in repeated cesarean section
Trial: NCT01154153
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
Trial: NCT01154153
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>= 6 yrs to \<12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.
Trial: NCT01154153
Drug: Claritin® Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
Trial: NCT02152787
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00359437
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration once daily